Q2 Earnings Estimate for Medpace Issued By Leerink Partnrs

Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) - Equities researchers at Leerink Partnrs lifted their Q2 2025 EPS estimates for shares of Medpace in a research note issued on Tuesday, July 8th. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $2.93 per share for the quarter, up from their prior forecast of $2.76. Leerink Partnrs has a "Hold" rating on the stock. The consensus estimate for Medpace's current full-year earnings is $12.29 per share. Leerink Partnrs also issued estimates for Medpace's Q4 2025 earnings at $3.11 EPS and FY2028 earnings at $15.92 EPS.

MEDP has been the subject of a number of other research reports. Truist Financial dropped their price objective on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a research note on Wednesday, April 23rd. Barclays started coverage on Medpace in a report on Tuesday, June 24th. They set an "equal weight" rating and a $300.00 price objective on the stock. Leerink Partners began coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 target price for the company. Mizuho decreased their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Finally, TD Cowen lowered Medpace from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $370.00 to $328.00 in a research note on Monday, April 14th. Twelve analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Medpace has a consensus rating of "Hold" and a consensus target price of $344.82.

Medpace Stock Up 2.3%

MEDP stock traded up $7.29 during mid-day trading on Thursday, reaching $328.24. 415,875 shares of the stock traded hands, compared to its average volume of 377,726. The firm has a market capitalization of $9.43 billion, a PE ratio of 24.50, a P/E/G ratio of 5.77 and a beta of 1.47. The business has a 50-day moving average of $304.73 and a two-hundred day moving average of $319.06. Medpace has a 52 week low of $250.05 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping the consensus estimate of $3.06 by $0.61. The company had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. Medpace had a net margin of 19.31% and a return on equity of 54.36%. During the same period in the previous year, the firm posted $3.20 earnings per share.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in MEDP. Geneos Wealth Management Inc. increased its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after buying an additional 37 shares during the period. Brooklyn Investment Group increased its holdings in Medpace by 244.8% during the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after acquiring an additional 71 shares during the period. SBI Securities Co. Ltd. bought a new stake in Medpace during the 4th quarter worth approximately $31,000. Whittier Trust Co. lifted its stake in Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its position in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after purchasing an additional 110 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Insider Activity

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director directly owned 2,998 shares in the company, valued at approximately $904,856.36. The trade was a 36.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.30% of the stock is currently owned by corporate insiders.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.